/C O R R E C T I O N -- Johnson & Johnson/
MWN-AI** Summary
On March 3, 2026, Johnson & Johnson announced that its investigational therapy nipocalimab received Fast Track designation from the U.S. Food and Drug Administration (FDA) as a potential treatment for adults with systemic lupus erythematosus (SLE). This designation highlights the unmet medical need and aims to expedite the review and development process for therapies related to serious conditions such as SLE, which affects approximately 3 to 5 million people globally.
Data from a Phase 2 clinical study indicated that nipocalimab could significantly reduce lupus disease activity and demonstrate steroid-sparing potential. The drug is an immunoselective treatment designed to lower harmful immunoglobulin G (IgG) antibodies, a principal driver of autoantibody-induced diseases, while preserving essential immune functions. The recent designation marks nipocalimab's fifth FDA Fast Track designation.
Johnson & Johnson is currently enrolling participants for a Phase 3 study, known as GARDENIA, to further evaluate nipocalimab's effectiveness in adults with active SLE. SLE is a complex autoimmune disease that can lead to chronic inflammation and damage across various organs, severely impacting the patients’ quality of life.
In comments regarding the new designation, Leonard L. Dragone, M.D., Ph.D., highlighted the importance of advancing therapeutic options to meet the ongoing challenges faced by patients suffering from this debilitating disease. Richard Furie, M.D., emphasized that progress like this brings hope for the development of more targeted therapies to improve patient outcomes.
Nipocalimab is still under investigation, with no current approvals for the treatment of SLE, but its promising results might pave the way for an innovative approach in managing this complex condition.
MWN-AI** Analysis
Johnson & Johnson (NYSE: JNJ) has recently garnered significant attention within the financial markets following the announcement that its investigational therapy nipocalimab received Fast Track designation from the U.S. FDA for the treatment of systemic lupus erythematosus (SLE). With an estimated 3 to 5 million who suffer from SLE globally, this potential therapeutic breakthrough addresses a pressing unmet medical need, making Johnson & Johnson an attractive investment opportunity for growth-oriented investors.
The Fast Track designation is a pivotal indicator that could expedite the drug’s development and review process, enhancing JNJ’s prospects for market success. Analysts believe that if nipocalimab achieves positive Phase 3 trial results, it could significantly boost sales, particularly given the limited existing treatment options for SLE. The drug, which targets immunoglobulin G (IgG) ameliorating disease impacts, positions Johnson & Johnson strategically in the burgeoning immunotherapy market.
Despite the promising developments, potential investors should remain cautious. Johnson & Johnson still faces various regulatory and competitive risks. The biomedical landscape is rapidly evolving, and there are significant challenges inherent in clinical trials, particularly regarding the drug’s efficacy and safety. Market volatility in the healthcare sector can also affect stock performance as investor sentiment fluctuates based on trial announcements and regulatory decisions.
From a financial perspective, JNJ operates a diversified portfolio that not only includes pharmaceuticals but also consumer health products and medical devices. This diversification serves as a buffer against sector-specific downturns. For investors considering a position in Johnson & Johnson, current valuations appear reasonable against a backdrop of potential growth from nipocalimab, but vigilance regarding upcoming trial results and broader market conditions is crucial. A cautious approach, possibly considering dollar-cost averaging, is advisable to mitigate risk.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
/C O R R E C T I O N -- Johnson & Johnson/
PR Newswire
In the news release, Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE), issued 03-Mar-2026 by Johnson & Johnson over PR Newswire, we are advised by the company that the last sentence of the fifth paragraph has been amended. The complete, corrected release follows:
Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)
Fast Track designation reflects the unmet need in this serious disease and enables the potential for an accelerated FDA review timeline
The designation is supported by a Phase 2 study in which nipocalimab demonstrated reduction in lupus disease activity and potential for steroid sparing
Systemic lupus erythematosus is a debilitating, chronic autoantibody-driven disease affecting multiple organs, with limited treatment options and risk of irreversible organ damage
Johnson & Johnson is actively enrolling patients in a Phase 3 study of adults with active systemic lupus erythematosus
SPRING HOUSE, Pa., March 3, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that nipocalimaba was granted U.S. Food and Drug Administration (FDA) Fast Track designation as a potential treatment for adults with systemic lupus erythematosus (SLE), a debilitating autoantibody-driven disease that impacts approximately 3 to 5 million people worldwide.1 The U.S. FDA's Fast Track designation program is designed to expedite the development and review timelines of drugs that demonstrate the potential to treat serious conditions, aiming to deliver therapeutics to patients more quickly in areas, like SLE, where unmet needs remain.2
"Nipocalimab earning its fifth FDA Fast Track designation, now in systemic lupus erythematosus, reflects the importance of accelerating the delivery of an immunoselective therapy that could fill an unmet need in this serious condition," said Leonard L. Dragone, M.D., Ph.D., Disease Area Leader, Autoantibody and Rheumatology, Johnson & Johnson. "This is an important step in our efforts to help address the ongoing burden faced by people living with this debilitating disease. Through close collaboration with the FDA, we seek to advance the development of nipocalimab as a potential new treatment option for the SLE patient community."
SLE affects multiple organs including the skin, joints, kidneys, blood and central nervous systems, with associated chronic signs and symptoms including severe fatigue, pain, swelling and rashes.3 Patients are at risk of irreversible organ damage due to systemic inflammation, disease flares and a reliance on steroids.4 These factors can significantly reduce quality of life, which highlights the critical unmet need for additional treatment options. Nipocalimab is an immunoselective investigational therapy that lowers harmful immunoglobulin G (IgG), one of the root causes of autoantibody-driven diseases, while also preserving critical immune functions.
"Systemic lupus erythematosus is a serious, complex disease that affects many aspects of a patient's life, and treatment options remain limited," said Richard Furie, M.D., Chief of the Division of Rheumatology at Northwell Health.b "Progress like this brings renewed hope for more targeted therapies and meaningful outcomes for people living with this devastating disease."
Following the positive Phase 2b JASMINE results, Johnson & Johnson initiated patient enrollment for the Phase 3 GARDENIA study of adults with active SLE. Nipocalimab is the only FcRn blocker to demonstrate reduction in SLE disease activity, as shown in the JASMINE study. The study met the primary endpoint and multiple key secondary and exploratory endpoints, including those indicating the potential of nipocalimab for steroid sparing.5
Editor's notes:
a. Nipocalimab is not approved in SLE.
b. Dr. Richard Furie has provided consulting, advisory and speaking services to Johnson & Johnson. He has not been paid for any media work.
ABOUT JASMINE
JASMINE (NCT04882878) is a 52-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study of nipocalimab in 228 adult participants with active SLE and the first positive study of an FcRn blocker for the treatment of active SLE.5
ABOUT SYSTEMIC LUPUS ERYTHEMATOSUS
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that occurs when the body's immune system mistakenly attacks its own healthy tissues. This can lead to inflammation and damage in many parts of the body, including the skin, joints, heart, lungs, kidneys, and brain.4 SLE affects nine times more women than men, often striking initially between the ages of 15-44.6 In addition to systemic organ damage, other complications of SLE can include end-stage renal failure, scarring cutaneous lesions, neurological damage, and various forms of cardiovascular disease.4 People living with SLE often face reduced health-related quality of life, due to severe fatigue, mood disturbances, joint pain and swelling, and rashes, including the hallmark butterfly-shaped facial rash, as well as complications of long-term glucocorticoid use.3 Severe fatigue is the most widely reported and debilitating symptom of SLE, affecting up to 80% of people with SLE.7 SLE is the most common form of lupus, affecting 3 to 5 million people worldwide, approximately 70% of lupus cases.1,6 It is estimated that 450,000 people in the United States are affected by SLE.8
ABOUT NIPOCALIMAB
Nipocalimab is an investigational immunoselective treatment designed to target, bind with high affinity, and block FcRn, reducing circulating IgG antibodies that drive disease while also preserving key immune functions. Nipocalimab is being investigated across three key segments in the autoantibody space including Rheumatologic disease, Rare Autoantibody diseases, Maternal Fetal diseases mediated by maternal alloantibodies in which blockade of IgG binding to FcRn in the placenta is also believed to limit transplacental transfer of maternal alloantibodies to the fetus.9,10,11,12,13,14,15,16,17,18
The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have granted several key designations to nipocalimab including:?
- EU EMA Orphan medicinal product designation for hemolytic disease of the fetus and newborn (HDFN) in October 2019 and fetal and neonatal alloimmune thrombocytopenia (FNAIT) in April 2025
- U.S. FDA Fast Track designation in HDFN and warm autoimmune hemolytic anemia (wAIHA) in July 2019, gMG in December 2021, FNAIT in March 2024, Sjögren's disease (SjD) in March 2025, and systemic lupus erythematosus (SLE) in January 2026
- U.S. FDA Orphan drug status for wAIHA in December 2019, HDFN in June 2020, gMG in February 2021, chronic inflammatory demyelinating polyneuropathy (CIDP) in October 2021 and FNAIT in December 2023
- U.S. FDA Breakthrough Therapy designation for HDFN in February 2024 and for SjD in November 2024
- U.S. FDA granted Priority Review in generalized myasthenia gravis in Q4 2024
ABOUT JOHNSON & JOHNSON
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.
Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com.
Follow us at @JNJInnovMed.
Janssen Research & Development, LLC, Janssen Biotech, Inc. and Janssen Global Services, LLC are Johnson & Johnson companies.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of nipocalimab. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
1 Tian, J., Zhang, D., Yao, X., Huang, Y., & Lu, Q. (2023). Global epidemiology of systemic lupus erythematosus: A comprehensive systematic analysis and modelling study. Annals of the Rheumatic Diseases, 82(3), 351–356. https://doi.org/10.1136/ard-2022-223035 | |||||||
2 U.S. Food and Drug Administration. Fast Track. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track. Last accessed: February 2026 | |||||||
3 Centers for Disease Control and Prevention. (2024). Symptoms of lupus. https://www.cdc.gov/lupus/signs-symptoms/. Last accessed: March 2026. | |||||||
4 National Institute of Arthritis and Musculoskeletal and Skin Disease. (2022) Systemic Lupus Erythematosus (Lupus). https://www.niams.nih.gov/health-topics/lupus. Last accessed: March 2026. | |||||||
5 ClinicalTrials.gov Identifier: NCT04882878. Available at: https://clinicaltrials.gov/study/NCT04882878. Last accessed: March 2026 | |||||||
6 Lupus Foundation of America. Lupus facts and statistics. https://www.lupus.org/resources/lupus-facts-and-statistics. Last accessed: March 2026. | |||||||
7 Ahn, G.E., & Ramsey-Goldman, R. (2012). Fatigue systemic lupus erythematosus. International Journal of Clinical Rheumatology, 7(2), 217–227. https://doi.org/10.2217/IJR.12.4 | |||||||
8 Wang, Y., Hester, L. L., Lofland, J., Rose, S., Karyekar, C.S., Kern, D.M., Blacketer, M., Davis, K., & Sheilds-Tuttle, K. (2022). Update on the prevalence of diagnosed systemic lupus erythematosus (SLE) by major health insurance types in the US in 2016. BMC Research Notes, 15, 5. https://doi.org/10.1186/s13104-021-05877-1 | |||||||
9 ClinicalTrials.gov Identifier: NCT04951622. Available at: https://clinicaltrials.gov/ct2/show/NCT04951622. Last accessed: March 2026. | |||||||
10 ClinicalTrials.gov. NCT03842189. Available at: https://clinicaltrials.gov/ct2/show/NCT03842189. Last accessed: March 2026. | |||||||
11 ClinicalTrials.gov Identifier: NCT05327114. Available at: https://www.clinicaltrials.gov/study/NCT05327114. Last accessed: March 2026. | |||||||
12 ClinicalTrials.gov Identifier: NCT04119050. Available at: https://clinicaltrials.gov/study/NCT04119050. Last accessed: March 2026. | |||||||
13 ClinicalTrials.gov Identifier: NCT05379634. Available at: https://clinicaltrials.gov/study/NCT05379634. Last accessed: March 2026. | |||||||
14 ClinicalTrials.gov Identifier: NCT05912517. Available at: https://www.clinicaltrials.gov/study/NCT05912517. Last accessed: March 2026. | |||||||
15 ClinicalTrials.gov Identifier: NCT04968912. Available at: https://clinicaltrials.gov/study/NCT04968912. Last accessed: March 2026. | |||||||
16 ClinicalTrials.gov Identifier: NCT04882878. Available at: https://clinicaltrials.gov/study/NCT04882878. Last accessed: March 2026. | |||||||
17 ClinicalTrials.gov Identifier: NCT06449651. Available at: https://clinicaltrials.gov/study/NCT06449651. Last accessed: March 2026. | |||||||
18 ClinicalTrials.gov Identifier: NCT06533098 Available at: https://clinicaltrials.gov/study/NCT06533098. Last accessed: March 2026. |
Media contact:
Bridget Kimmel
bkimmel@its.jnj.com
Investor contact:
Jessica Margevich
investor-relations@its.jnj.com
SOURCE Johnson & Johnson
FAQ**
How does the FDA Fast Track designation for nipocalimab benefit Johnson & Johnson JNJ in terms of competitive advantage and market potential within the systemic lupus erythematosus treatment landscape?
What specific outcomes from the Phase 2 study support Johnson & Johnson JNJ's claims about nipocalimab's effectiveness in reducing lupus disease activity?
Given the high unmet need for treatments in systemic lupus erythematosus, how does Johnson & Johnson JNJ plan to leverage the positive results of the JASMINE trial in its marketing and development strategy?
What risks does Johnson & Johnson JNJ face in the ongoing development of nipocalimab, and how might these impact its investment appeal in the biopharmaceutical sector?
**MWN-AI FAQ is based on asking OpenAI questions about Johnson & Johnson (NYSE: JNJ).
NASDAQ: JNJ
JNJ Trading
1.98% G/L:
$243.06 Last:
2,893,360 Volume:
$240.87 Open:
